Comparing 22 vendors in Women Health Diagnostics across 0 criteria.
Become a Client
- Access Exclusive Reports, expert insights and tailored support to drive growth.
The Women's Health Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Women's Health Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 50 companies of which the Top 22 Women's Health Diagnostics Companies were categorized and recognized as the quadrant leaders.
Women's health refers to the medical specialty that focuses on management and care of clinical conditions that affects female physical or mental health. Few major clinical conditions related to women’s health include specific cancers (uterine cancer, cervical cancer, breast cancer, etc.), fibroids (breast fibroids, uterine fibroids, etc.), osteoporosis, reproductive/fertility-related conditions, dense breast tissues (DBT), menorrhagia, etc.
Specialized medical imaging technologies are utilized to diagnose various women’s health conditions including ultrasound, mammography, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), thermography, imaging modalities (used for guided biopsy), bone densitometers, etc.
The 360 Quadrant maps the Women's Health Diagnostics companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Women's Health Diagnostics’ quadrant. While the top criteria for product footprint evaluation included Breadth of Offerings (2D Ultrasound, 3D Ultrasound, CT, FFDM, Biopsy - image guided or contrast, MRI, 3D Tomosynthesis, Molecular imaging, Thermography, Bone densitometry), Product Category Offered (Comprehensive Technology Solutions, Contrast Agents, Software, Systems, Services), Application Category Offered (Breast Cancer, Cervical Cancer, Ovarian Cancer, Uterine Cancer, Bone Metastasis, Fertility Monitoring, Menorrhagia, Fibroids & DBT), Dedicated portfolio/website for Women’s health, Product Launches & Approvals (AI-based Products Launch/Approval), Geography Specific Launch/Approval, (North America, Europe, Asia-Pacific, Middle East and Africa, Latin America), Value Addition And Company USP (Training and Education Services, Predictive Maintenance Service Offerings, Awareness Campaigns).
Key trends highlighted in 360 Quadrant’s study include:
- The global market for women's health diagnostics, in terms of revenue, is expected to reach USD 36.6 billion by 2025. The market's expansion is primarily fueled by increasing awareness of various health-related conditions, the escalating incidence of chronic and lifestyle diseases, and the prevalent occurrence of infectious diseases like HIV and hepatitis among women worldwide. Furthermore, the rising adoption of point-of-care (POC) diagnostic testing and the proliferation of diagnostic and imaging centers are anticipated to bolster market growth. However, challenges such as the high cost of diagnostic devices, tests, and procedures, a shortage of skilled laboratory technicians, and inadequate reimbursements for diagnostic tests are expected to temper the market's growth to some extent.
- In 2023, North America led the women's health diagnostics industry in market share, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. The significant market share in this region stems from the rising incidence of cancer among women, the concerted efforts of women's health diagnostic product manufacturers to extend their footprint here, and the growing need for fertility testing monitors. Furthermore, the increasing adoption of point-of-care diagnostics and preventative screening and testing practices is anticipated to fuel the expansion of this regional sector in the foreseeable future.
- Women's Health Diagnostics Companies are adopting various strategies such as geographic expansions, new product launches, partnerships, and acquisitions to accelerate their position in the market. The key players have been trying to strengthen their product & service portfolios and cater to the untapped markets. For instance, in January 2024, Hologic, unveiled that its latest innovation, the Genius Digital Diagnostics System featuring the Genius Cervical AI algorithm, has been granted clearance by the U.S. Food and Drug Administration (FDA). This achievement marks it as the pioneering digital cytology system to receive FDA clearance, integrating state-of-the-art deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology. Its primary purpose is to aid in the detection of pre-cancerous lesions and cervical cancer cells. Similarly, in October 2023, Philips unveiled its latest advancements in OB/GYN ultrasound at ISUOG 2023, aimed at enhancing early detection and diagnostic confidence.
- The high prevalence of infectious diseases in women creates significant opportunities for Women's Health diagnostics companies. Women are disproportionately affected by various infections, necessitating accurate and timely diagnostics for early detection and treatment. Advanced technologies in molecular diagnostics and point-of-care testing are crucial in identifying infectious agents promptly. As the demand for innovative diagnostic solutions rises, Women's Health diagnostics companies stand to benefit from the expanding market and increased focus on women's health issues.
- The improvement of healthcare infrastructure in emerging healthcare markets serves as a significant driver for the women's health diagnostics market. As these regions undergo infrastructural enhancements, including the establishment of medical facilities, expansion of healthcare coverage, and increased accessibility to diagnostic services, there emerges a greater awareness and demand for women's health diagnostics. Improved infrastructure facilitates better access to healthcare services, leading to more women seeking preventative screenings and diagnostic tests. This surge in demand creates a favorable environment for women's health diagnostics companies to expand their market presence and introduce innovative diagnostic solutions tailored to the specific needs of women. Additionally, as healthcare infrastructure improves, regulatory frameworks may evolve to support the adoption of advanced diagnostic technologies, providing further opportunities for companies in this sector to thrive and innovate.